So sánh kết quả lâu dài giữa hóa xạ trị đồng thời phác đồ Folfox so với phác đồ CF trong điều trị ung thư thực quản giai đoạn không mổ được tại Bệnh viện K và Bệnh viện Ung bướu tỉnh Thanh Hóa

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Quang Hưng Nguyễn, Thị Thu Hường Nguyễn, Thị Tố Quyên Nguyễn, Tuyết Mai Nguyễn, Văn Xuân Võ

Ngôn ngữ: vie

Ký hiệu phân loại: 616.994 +Cancers

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2022

Mô tả vật lý: 84-88

Bộ sưu tập: Metadata

ID: 499346

Thêm vào giỏ

So sánh kết quả điều trị ung thư thực quản giai đoạn không mổ được bằng hóa xạ trị đồng thời phác đồ FOLFOX và CF
độc tính và tác dụng không mong muốn của phác đồ. Đối tượng và phương pháp: Nghiên cứu can thiệp tiến cứu, có nhóm chứng trên 102 bệnh nhân ung thư thực quản giai đoạn không mổ được điều trị hóa xạ trị đồng thời chia làm 2 nhóm: nhóm nghiên cứu điều trị với phác đồ FOLFOX và nhóm chứng điều trị với phác đồ CF kết hợp tia xạ liều 50Gy/5 tuần, phân liều 2Gy/ngày. Kết quả: Tỷ lệ sống thêm toàn bộ 12 tháng, 18 tháng và 24 tháng ở nhóm nghiên cứu là 90,1%, 64,7% và 45,1%
ở nhóm chứng là 84,3%, 54,9% và 39,2%
p = 0,56. Sống thêm toàn bộ trung bình là 19,9 ± 0,81 tháng so với 18,4± 0,79 ở nhóm chứng, p = 0,67
sống thêm không tiến triển trung bình là 18,5± 0,89 tháng so với 17,2± 0,90 ở nhóm chứng, p = 0,59. Một số yếu tố ảnh hưởng đến kết quả điều trị là kích thước u, giai đoạn bệnh, gián đoạn điều trị và sự đáp ứng điều trị. Độc tính (huyết học , gan , thận, các cơ quan khác) đa phần gặp độ I, II. Kết luận: Phác đồ FOLFOX so với phác đồ CF cho hiệu quả tương đương về tỷ lệ đáp ứng, thời gian sống thêm toàn bộ cũng như sống thêm không tiến triển và có phần trội hơn trên nhóm bệnh nhân giai đoạn muộn
đồng thời phác đồ FOLFOX ít ảnh hưởng lên toàn trạng, chức năng thận và ít gây buồn nôn, nôn, rụng tóc một cách rõ rệt so với phác đồ CF.To evaluate the results of treatment of inoperable stage esophageal cancer with chemoradiotherapy concurrently with the FOLFOX regimen
toxicity and side effects of the regimen. Subjects and methods: Prospective intervention study, with a control group on 102 patients with non-operative esophageal cancer who received chemoradiotherapy concurrently and divided into 2 groups: study group treated with FOLFOX regimen and control group treated with CF regimen combined with radiation dose of 50Gy/5 weeks, divided dose of 2Gy/day. Results: The rate of complete and partial response in the study group was 27.5% and 64.6%, 25.5% and 60.8% higher than that of the control group
p = 0.78. The rate of complete response according to disease stage II, III in the study group and control group was 33.3%, 23.3% and 33.3%, 20.0%, respectively
p >
0.05. Overall survival rate of 12 months, 18 months and 24 months in the study group was 90.1%, 64.7% and 45.1%
in the control group were 84.3%, 54.9% and 39.2%
p = 0.56. The overall median survivalwas 19.9 ± 0.81 months compared with 18.4 ± 0.79 in the control group, p = 0.67
Meanprogression-free survival (PFS)was 18.5± 0.89 months compared with 17.2± 0.90 in the control group, p = 0.59. Some factors affecting treatment outcome are tumor size, disease stage, treatment interruption and treatment response. Toxicity (hematology, liver, kidney, other organs) is mostly grade I, II. Conclusion:The FOLFOX regimen compared with the CF regimen showed similar efficacy in response rate, overall survival as well as progression-free survival and was somewhat superior in the group of late stage patients
At the same time, the FOLFOX regimen had little effect on the general condition, renal function and significantly less nausea, vomiting, and hair loss than the CF regimen. The FOLFOX regimen should be widely used in the treatment of inoperable esophageal cancer stage and should be considered the first choice.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR